Could this be a game-changer for anaphylaxis treatment? For the first time in over three decades, Australia has approved a new method of delivering adrenaline, and it’s not an injection. The Therapeutic Goods Administration (TGA) has given the green light to Neffy, an adrenaline (epinephrine) nasal spray, sparking both excitement and questions in the medical community. But here's where it gets controversial: while some hail it as a breakthrough, others wonder if it’s truly a step forward or just a pricey alternative. Let’s dive in.
Neffy’s arrival is significant because it offers a needle-free option for treating anaphylaxis, a life-threatening allergic reaction that requires immediate intervention. Professor Connie Katelaris AM, a leading allergist in NSW, welcomes the addition: ‘Anaphylaxis is notoriously challenging to manage, and having another tool in our arsenal is a positive step. Patients in Australia now have access to something that’s been available overseas for years.’ But is it as effective as the tried-and-true EpiPen? And this is the part most people miss: its higher cost and prescription-only status might limit its accessibility.
How Does Neffy Compare to EpiPen?
Both Neffy and EpiPen deliver adrenaline, the critical ingredient for halting anaphylaxis. However, Neffy does so through the nasal mucosa, bypassing the need for a needle. This makes it a potential game-changer for those with needle phobia, particularly young children. But there’s a catch: Neffy is currently a Schedule 4 medication, meaning it requires a prescription, while EpiPen is more readily available in resuscitation kits as a Schedule 3 item. Will this limit its use in emergency situations?
Who Can Use Neffy?
Neffy is approved for patients aged 4 and older, weighing at least 15 kg. It comes in two strengths: 1 mg for patients weighing 15–30 kg and 2 mg for those over 30 kg. However, it’s not suitable for children under 4 or those under 15 kg, where adrenaline auto-injectors remain the only option. This raises the question: Is Neffy filling a gap or creating a new divide in anaphylaxis care?
Potential Risks and Challenges
While Neffy offers a needle-free alternative, it’s not without risks. Patients with conditions like raised intraocular pressure, severe renal impairment, or cardiovascular disease may face increased adverse effects. Additionally, those with nasal structural issues—such as polyps or previous nasal injuries—might find it less effective due to uncertain absorption rates. Is this a minor concern or a significant limitation?
Cost and Accessibility
At $194 for a box containing two nasal sprays, Neffy is about 20% more expensive than EpiPen. CSL Seqirus, the manufacturer, has applied for it to be listed on the Pharmaceutical Benefits Scheme (PBS), but this won’t be decided until March 2026. Until then, will its cost outweigh its benefits for many families?
The Future of Neffy
CSL Seqirus is also seeking to downschedule Neffy to Schedule 3, which would make it more accessible. If approved, this could position it as a viable alternative to EpiPen. But with its higher price tag and pending PBS listing, is Neffy a luxury or a necessity?
Final Thoughts
Neffy’s introduction is undoubtedly a milestone in anaphylaxis care, but it’s not without its controversies. Is it worth the price? Will it truly improve accessibility? And how will it fit into existing emergency protocols? These questions remain open for debate. What do you think? Is Neffy a step forward, or does it fall short of expectations? Share your thoughts in the comments below!
